Ublituximab
UTX-TGR-203
Phase 2 small_molecule terminated
Quick answer
Ublituximab for Follicular Lymphoma is a Phase 2 program (small_molecule) at TG THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TG THERAPEUTICS, INC.
- Indication
- Follicular Lymphoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated